Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $16.72, for a total value of $133,760.00. Following the transaction, the insider now directly owns 8,000 shares in the company, valued at $133,760. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) traded up $0.24 during trading on Tuesday, reaching $17.03. The company had a trading volume of 1,016,900 shares, compared to its average volume of 1,110,379. Corcept Therapeutics Incorporated has a 1-year low of $6.70 and a 1-year high of $20.77. The company has a market capitalization of $1,916.15, a P/E ratio of 57.90 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The company had revenue of $42.70 million for the quarter, compared to the consensus estimate of $41.64 million. During the same quarter last year, the company posted $0.02 EPS. The company’s quarterly revenue was up 96.8% compared to the same quarter last year. sell-side analysts expect that Corcept Therapeutics Incorporated will post 0.47 EPS for the current fiscal year.

Several equities research analysts recently issued reports on the company. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Piper Jaffray Companies set a $30.00 price target on Corcept Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Stifel Nicolaus assumed coverage on Corcept Therapeutics in a report on Thursday, August 31st. They set a “buy” rating and a $20.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $18.20.

A number of institutional investors have recently made changes to their positions in CORT. Marshall Wace North America L.P. bought a new position in Corcept Therapeutics in the 2nd quarter valued at $13,942,000. Renaissance Technologies LLC grew its stake in Corcept Therapeutics by 44.4% in the 2nd quarter. Renaissance Technologies LLC now owns 2,683,400 shares of the biotechnology company’s stock valued at $31,664,000 after purchasing an additional 824,900 shares during the period. Vanguard Group Inc. grew its stake in Corcept Therapeutics by 18.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,440,064 shares of the biotechnology company’s stock valued at $52,394,000 after purchasing an additional 689,554 shares during the period. Teachers Advisors LLC grew its stake in Corcept Therapeutics by 316.9% in the 2nd quarter. Teachers Advisors LLC now owns 817,245 shares of the biotechnology company’s stock valued at $9,643,000 after purchasing an additional 621,219 shares during the period. Finally, Wells Fargo & Company MN grew its stake in Corcept Therapeutics by 644.4% in the 3rd quarter. Wells Fargo & Company MN now owns 715,261 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 619,180 shares during the period. Institutional investors and hedge funds own 64.71% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/12/robert-s-fishman-sells-8000-shares-of-corcept-therapeutics-incorporated-cort-stock.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.